TY - JOUR
T1 - Hexamethylmelamine
T2 - An evaluation of its role in the treatment of ovarian cancer
AU - Wharton, J. Taylor
AU - Rutledge, Felix
AU - Smith, Julian P.
AU - Herson, Jay
AU - Hodge, M. Pat
N1 - Funding Information:
Research supported in part by Grant NOI-CM-33710 the Department of Gynecology and Research Grant CA-l 1430 to the Department of Biomathematics, from the National Cancer Institute.
PY - 1979/4/1
Y1 - 1979/4/1
N2 - Hexamethylmelamine (HMM), NSC 13875, a synthetic agent structurally related to triethylenemelamine, has clinical antitumor activity and a role in the treatment of ovarian cancers of epithelial origin. Fifty-four patients, with International Federation of Gynecology and Obstetrics Stage III or IV carcinomas, previously untreated with chemotherapy or irradiation therapy, were treated with HMM (8 mg/kg/day) as a single agent at the M. D. Anderson Hospital and Tumor Institute in Houston, Texas, between January, 1973, and May, 1976. The response end points analyzed were complete plus partial response rate, duration of remission, and survival time. The complete and partial responses were verified whenever possible by "second-look" operation. Seventeen patients (31.8%) responded to HMM and three had no evidence of cancer, determined by multiple biopsies at second-look operation. Gastrointestinal, hematologic, and nervous system toxic effects were severe in 10 patients, requiring discontinuation of HMM. This study shows that HMM can induce a complete response and provide an extended disease-free interval without maintenance chemotherapy.
AB - Hexamethylmelamine (HMM), NSC 13875, a synthetic agent structurally related to triethylenemelamine, has clinical antitumor activity and a role in the treatment of ovarian cancers of epithelial origin. Fifty-four patients, with International Federation of Gynecology and Obstetrics Stage III or IV carcinomas, previously untreated with chemotherapy or irradiation therapy, were treated with HMM (8 mg/kg/day) as a single agent at the M. D. Anderson Hospital and Tumor Institute in Houston, Texas, between January, 1973, and May, 1976. The response end points analyzed were complete plus partial response rate, duration of remission, and survival time. The complete and partial responses were verified whenever possible by "second-look" operation. Seventeen patients (31.8%) responded to HMM and three had no evidence of cancer, determined by multiple biopsies at second-look operation. Gastrointestinal, hematologic, and nervous system toxic effects were severe in 10 patients, requiring discontinuation of HMM. This study shows that HMM can induce a complete response and provide an extended disease-free interval without maintenance chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0018372170&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018372170&partnerID=8YFLogxK
U2 - 10.1016/0002-9378(79)90120-0
DO - 10.1016/0002-9378(79)90120-0
M3 - Article
C2 - 219695
AN - SCOPUS:0018372170
SN - 0002-9378
VL - 133
SP - 833
EP - 844
JO - American journal of obstetrics and gynecology
JF - American journal of obstetrics and gynecology
IS - 7
ER -